AstraZeneia PARP inhibitors are to be included in the priority review and two new drugs have been approved clinically

1. Olapali mechanism: PARP inhibitors To develop adhesives: single-drug treatment for adult patients with specific metastatic desopathic prostate cancer Olapali is a "first-in-class" PARP inhibitor jointly developed by AstraZeneza and MSD, and the first approved PARP inhibitor.
target DNA damage repair response (DDR) path, using the principle of "synthetic death" to kill cancer cells without affecting healthy cells.
the drug was first approved in the U.S. in December 2014 to treat patients with advanced ovarian cancer who carry a mutation in the BRCA lineage gene.
This time Olapali is to be included in a priority review in China to develop a monodrative treatment (developed) for adult patients with BRCA1/2 mutations (embryo and/or somatic cell line) and progression of the disease after the treatment of previous new hormone drugs.
Screenshot Source: According to the results of a Phase 3 clinical trial called PROfound, olapali improved the total survival of patients (OS) significantly compared to abitron or entramine in mCRPC patients carrying BRCA1/2 or ATM gene mutation substations, reaching a critical secondary endpoint of the trial.
previously published trial results showed that in mCRPC patients with BRCA1/2 or ATM mutations, Olapali's treatment significantly extended the patient's radiological progression-free life (rPFS) compared to abitor or entrumane, reaching the main end of the trial.
, Olapali (Chinese trade name: Liptro) was first approved in August 2018 and is the first new drug to be approved for ovarian cancer to be approved in China.
November 2019, Olapali was again approved by the NMPA for first-line maintenance therapy for patients with advanced ovarian cancer with BRCA gene mutations who were relieved after receiving platinum-based chemotherapy.
2, benralizumab injection mechanism: IL-5R alpha inhibitors Approved clinical adaptation: Chronic Obstructive Pulmonary Disease (COPD) Benralizumab (Fasenra) is a monoclonal antibody developed by AstraZenecon in combination with il-5R alpha expressed on the surface of acidic granulocytes.
by combining with IL-5R alpha, it is able to collect natural killer cells and quickly remove them by inducing the apoptosis process of acidic granulocytes.
studies have shown that selective anti-eosinophils can reduce acute exacerbation rates in COPD patients, which appears to be more pronounced in patients with a high base of hemophilic acidophils.
previously, Benralizumab was approved by the FDA in November 2017 for additional maintenance therapy for patients with severe asthma who are 12 years of age and older with eosinophilic ideopathy.
addition, it was awarded orphan drug eligibility by the FDA in 2018 and 2019 for the treatment of eosinophilic multivascularitis (EGPA) and for the treatment of high eosinophil syndrome (HES).
the Benralizumab injection was approved clinically in China to develop an adaptive disease called chronic obstructive pulmonary disease.
is an aggressive disease that can cause blockages in the lungs, causing breathing difficulties.
affects about 384 million people worldwide, the third leading cause of death in the world.
improving lung function, reducing acute exacerbation and managing daily symptoms are important therapeutic goals in DPR management.
Based on the clinical results of a project called WINDWARD, patients with severe asthma who received the 8-week benralizumab dosing program had significant improvements in lung function, a 1-second strong exhalation volume (FEV1) increased by 159ml over the placebo group, and saw differences after 4 weeks of dosing, suggesting early effect.
studies have shown that benralizumab has strong clinical manifestations, including the ability to improve lung function after the first drug, the potential to reduce or even stop using oral steroids, and the ease of taking medication at 8 weeks.
Screenshot Source: CDE Official Website 3, tezepelumab Injection Mechanism: TSLP Inhibitors Approved Clinical Adaptations: Severe Chronic Sinusitis with Nasal Diphtheria Public data show that tezepelumab is a thymus-based lymphocyte production (TSLP) inhibitor jointly developed by Amgen and AstraZeneca, a potential "first-in-class" new drug that has been identified as a potential "first-in-class" drug.
TSLP is an upper-level regulator of multiple inflammatory pathways in a variety of diseases, including asthma, which is essential for the occurrence and ongoing of airway inflammation.
studies have shown that TSLP is active in regulating T2 immunity.
, it can also play a role in non-T2-driven inflammation by activating or signaling multiple types of cells, such as fat cells and alkaline granulocytes.
the tezepelumab injection was approved clinically in China to develop an adaptation to severe chronic sinusitis with nasal pyrophology (CRSwNP).
Chronic sinusitis with nasal pneumo meat affects up to 4% of the world's population, characterized by the presence of benign inflammatory pyre (nasal pyre) on the lining of the sinuses or nasal cavity, which can block normal airflow and lead to symptoms such as nasal congestion, runny nose, facial pain/stress and loss or loss of sense of smell.
studies have shown that the expression level of TSLP is positively correcipable with the expression of Th2 cytokines in the sinus mucous membrane, and that TSLP can induce the expression of ST2L in human primary nasal mucous membrane epithal cell culture.
in chronic nasal-sinusitis, where acidoblastoids are associated with nasal polyps, positive feedback rings and Th2 cytokines formed by TSLP and its subjects can promote the development of Th2 inflammatory responses.
, biologics for TSLP are expected to be a new option for treating sinusitis with nasal pythons.
currently, surgery and systemic corticosteroids are the main treatments for the disease after standard treatment of endotols.
, however, due to the rede growth of nasal pylodone, over time, they often fail to effectively control chronic symptoms.
: The Drug Review Center of the State Drug Administration of China. Retrieved Nov 27, 2019, from the results of Phase 2 of AstraZeneta's new drug Fasenra positively and almost completely remove pathogenic white blood cells. Retrieved April 8, 2019, from . (2004). The increase of acidic granulocytes in the channel and the exacerbation of COPD. Journal of Bioengineering, Modern Clinical Medicine, 79-81.doi:CNKI:SUN:XDLC.0.2004-01-043. [4] Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma. Retrieved September 7, 2018, from .5. (2017). Looking forward to the precise treatment of chronic nasal-sinusitis with nasal pyma. Chinese Journal of Otolaryngology Head and Neck Surgery doi:10.3760/cma.j.issn.1673-0860.2017.02.001. Liao Bo. TSLP, IL-33 and its subjects interact in the chronic nasal-sinusitis cortitis cortitis cells of acidophilic cells with nasal polyps. 2015. Source: Medical Mission Hills